ADMA Biologics (ADMA) Financial Statements & Analysis

ADMA Biologics (ADMA) Income Statement

ADMA Biologics reported revenue of $510.17M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 19.6% from $426.45M a year earlier. Net income was $146.93M, down 25.7% year over year, a net margin of 28.8%. Gross margin was 57.4% and operating margin 37.5%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $124.39M, up 2.0% from the same quarter a year earlier.

ADMA Biologics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

ADMA Biologics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	510.17	426.45	258.22	154.08	80.94	42.22	29.35	16.99	22.76
Cost of Revenue	217.41	206.90	169.27	118.82	79.77	53.79	39.50	42.19	29.16
Gross Profit	292.77	219.55	88.94	35.27	1.17	-11.57	-10.16	-25.21	-6.40
Operating Expenses
Research & Development	4.76	1.81	3.30	3.61	2.85	5.91	2.34	3.93	6.23
Selling, General & Administrative	96.42	78.37	62.59	52.46	55.19	39.22	25.91	22.50	18.09
Operating Expenses	101.32	80.57	67.31	74.63	59.55	45.84	31.27	35.08	32.06
Operating Income	191.44	138.98	21.63	-39.37	-58.37	-57.41	-41.42	-60.29	-39.31
Other Income/Expense
Interest Income	1.87	2.10	1.62	0.05	0.04	0.29	0.80	0.20	0.06
Interest Expense	7.11	-13.93	-25.03	19.28	-13.06	-11.99	8.99	5.52	3.29
Other Income/Expense	-17.57	-26.54	-99.74	-7.31	-26.55	-0.13	-6.85	-5.45	-4.45
Income
Income Before Tax	182.66	125.71	-28.24	-65.90	-71.65	-75.75	-48.28	-65.74	-43.76
Income Tax Expense	35.73	-71.96	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	146.93	197.67	-28.24	-65.90	-71.65	-75.75	-48.28	-65.74	-43.76
Net Income - Continuous Operations	146.93	197.67	-28.24	-65.90	-71.65	-75.75	-48.28	-65.74	-43.76
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	199.54	147.03	30.66	-39.51	-52.08	-53.47	-36.03	-56.77	-39.31
EBIT	191.44	138.98	22.33	-46.63	-57.57	-57.41	-	-	-
Depreciation & Amortization	8.10	8.05	8.33	0.72	5.50	3.94	3.26	3.45	1.23
Earnings Per Share
Basic EPS	1.00	1.00	-	-	-1.00	-1.00	-1.00	-1.00	-2.00
Diluted EPS	1.00	1.00	-	-	-1.00	-1.00	-1.00	-1.00	-2.00
Basic Shares Outstanding	238.30	233.08	223.98	197.87	139.58	86.15	54.35	45.19	22.90
Diluted Shares Outstanding	244.90	233.08	223.98	197.87	139.58	86.15	54.35	45.19	22.90

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About ADMA Biologics Financial Statements

What was ADMA Biologics's revenue in fiscal 2025?

ADMA Biologics reported revenue of $510.17M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 19.6% from $426.45M a year earlier.

Is ADMA Biologics profitable?

Yes. ADMA Biologics earned net income of $146.93M in fiscal 2025, a net margin of 28.8%. In fiscal 2024 it earned $197.67M.

What is ADMA Biologics's operating margin?

ADMA Biologics's operating income was $191.44M on revenue of $510.17M in fiscal 2025, an operating margin of 37.5%, compared with 32.6% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition